Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 3, 2010, Pages 575-583

  Reinicke, Kathryn E ^a   Kuffel, Mary J ^a   Goetz, Matthew P ^a   Ames, Matthew M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aminoflavone; Camptothecin; Cytochrome P450; MCF 7; Paclitaxel

Indexed keywords

5 AMINO 6,8 DIFLUORO 2 (3 FLUOROPHENYL) 7 METHYL 4H 1 BENZOPYRAN 4 ONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; AFP 464; AMINOFLAVONE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; PACLITAXEL; UNCLASSIFIED DRUG; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DNA; DRUG DERIVATIVE; FLAVONOID; IRINOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE S PHASE; CENTRIFUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; BIOSYNTHESIS; BREAST TUMOR; CLONOGENIC ASSAY; DRUG EFFECT; ENZYME INDUCTION; FEMALE; METABOLISM; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DNA; DRUG SYNERGISM; ENZYME INDUCTION; FEMALE; FLAVONOIDS; HUMANS; PACLITAXEL;

EID: 77954675164     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1198-z     Document Type: Article

References (33)

1. Akama T, Shida Y, Sugaya T, Ishida H, Gomi K, Kasai M (1996) Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer. J Med Chem 39:3461-3469
2. Alley PE (1999) Rabbit news and research quarterly. Can Vet J 40:89
3. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349
4. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM (2002) Activation of the antitumor agent aminoflavone (nsc 686288) is mediated by induction of tumor cell cytochrome p450 1a1/1a2. Mol Pharmacol 62:143-153
5. Pobst LJ, Ames MM (2006) Cyp1a1 activation of aminoflavone leads to DNA damage in human tumor cell lines. Cancer Chemother Pharmacol 57:569-576
6. McLean L, Soto U, Agama K, Francis J, Jimenez R, Pommier Y, Sowers L, Brantley E (2008) Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells. Int J Cancer 122:1665-1674
7. Meng LH, Kohlhagen G, Liao ZY, Antony S, Sausville E, Pommier Y (2005) DNA-protein cross-links and replication-dependent histone h2ax phosphorylation induced by aminoflavone (nsc 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res 65:5337-5343
8. Forastiere AA, Shank D, Neuberg D, SGt Taylor, DeConti RC, Adams G (1998) Final report of a phase ii evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an eastern cooperative oncology group trial (pa390). Cancer 82:2270-2274
9. Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, Chua ET, Tan T, Khoo-Tan HS, Yang TL, Au E, Tao M, Ong YK, Chua EJ (1999) Phase ii trial of a paclitaxel and carboplatin combination in asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 10:235-237
10. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805
11. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA et al (1993) Paclitaxel and recombinant human granulocyte colonystimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951
12. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
13. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an eastern cooperative oncology group study. J Clin Oncol 13:1430-1435
14. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279
15. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753
16. Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E (1992) Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170
17. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage iii/iv ovarian cancer (from the gynecologic oncology group). Semin Oncol 23:40-47
18. Spratlin J, Sawyer MB (2007) Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol 61:222-229
19. Tubiana-Hulin M (2005) How to maximize the efficacy of taxanes in breast cancer. Cancer Treat Rev 31 (Suppl 4): S3-9
20. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983
21. Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G, Pommier Y (2001) Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, nb-506, and its topoisomerase I binding site. Cancer Res 61:504-508
22. Gupta M, Fujimori A, Pommier Y (1995) Eukaryotic DNA topoisomerases i. Biochim Biophys Acta 1262:1-14
23. Becerra CR, Verma UN, Tran HT, Tavana D, Williams NS, Frenkel EP (2008) Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. Am J Clin Oncol 31:219-225
24. Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL (2008) Phase II study of sequentially administered low-dose mitomycin-c (mmc) and irinotecan (cpt-11) in women with metastatic breast cancer (mbc). Ann Oncol 19:1417-1422
25. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR (2004) Randomized phase ii study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22:2849-2855
26. Taguchi T, Yoshida Y, Izuo M, Ishida T, Ogawa M, Nakao I, Tominaga T, Ohkawa T, Oguro M, Yoshida M et al (1994) An early phase II study of cpt-11 (irinotecan hydrochloride) in patients with advanced breast cancer. Gan To Kagaku Ryoho 21:83-90
27. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
28. Ernster L, Danielson L, Ljunggren M (1962) Dt diaphorase. I. Purification from the soluble fraction of rat-liver cytoplasm, and properties. Biochim Biophys Acta 58:171-188
29. Pommier Y (2006) Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer 6:789-802
30. Weaver BA, Cleveland DW (2005) Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 8:7-12
31. Meng LH, Shankavaram U, Chen C, Agama K, Fu HQ, Gonzalez FJ, Weinstein J, Pommier Y (2006) Activation of aminoflavone (nsc 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-h2ax. Cancer Res 66:9656-9664
32. Oberlies NH, Kroll DJ (2004) Camptothecin and taxol: historic achievements in natural products research. J Nat Prod 67:129-135
33. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF (2001) Ubiquitin/26s proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61:5926-5932